Published in J Pharmacol Toxicol Methods on June 01, 2005
High-sensitivity analysis of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.75
Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract (2010) 1.53
Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. Neurosurgery (2005) 1.24
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol (2011) 1.22
A liquid chromatography/mass spectrometric method for simultaneous analysis of arachidonic acid and its endogenous eicosanoid metabolites prostaglandins, dihydroxyeicosatrienoic acids, hydroxyeicosatetraenoic acids, and epoxyeicosatrienoic acids in rat brain tissue. J Pharm Biomed Anal (2006) 1.17
The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations. Pharmacol Ther (2010) 1.07
Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. Psychopharmacology (Berl) (2008) 1.04
Topiramate antagonizes NMDA- and AMPA-induced seizure-like activity in planarians. Pharmacol Biochem Behav (2009) 1.03
Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives. Curr Med Res Opin (2013) 1.02
Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J Pharmacol Exp Ther (2003) 1.01
Determination of bioactive eicosanoids in brain tissue by a sensitive reversed-phase liquid chromatographic method with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.00
An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 55212-2). Pharmacol Biochem Behav (2007) 0.97
The beta-lactam antibiotic ceftriaxone inhibits physical dependence and abstinence-induced withdrawal from cocaine, amphetamine, methamphetamine, and clorazepate in planarians. Eur J Pharmacol (2008) 0.97
A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract (2012) 0.97
Glutamate and aspartate measurements in individual planaria by rapid capillary electrophoresis. J Pharmacol Toxicol Methods (2010) 0.95
Nicotine behavioral pharmacology: clues from planarians. Drug Alcohol Depend (2011) 0.95
First evidence that drugs of abuse produce behavioral sensitization and cross sensitization in planarians. Behav Pharmacol (2010) 0.94
Transversus abdominis block: clinical uses, side effects, and future perspectives. Pain Pract (2013) 0.94
Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol (2009) 0.92
A nitric oxide synthase inhibitor (L-NAME) attenuates abstinence-induced withdrawal from both cocaine and a cannabinoid agonist (WIN 55212-2) in Planaria. Brain Res (2006) 0.91
Continuous multimechanistic postoperative analgesia: a rationale for transitioning from intravenous acetaminophen and opioids to oral formulations. Pain Pract (2011) 0.91
Effects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in mice. Psychopharmacology (Berl) (2011) 0.88
Sucrose produces withdrawal and dopamine-sensitive reinforcing effects in planarians. Physiol Behav (2013) 0.88
Development and validation of a high-performance liquid chromatography-electrospray mass spectrometry method for the simultaneous determination of 23 eicosanoids. J Pharm Biomed Anal (2007) 0.87
Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting. J Clin Anesth (2012) 0.86
Measurement of glutamate and aspartate in Planaria. J Pharmacol Toxicol Methods (2005) 0.85
On deriving the dose-effect relation of an unknown second component: an example using buprenorphine preclinical data. Drug Alcohol Depend (2010) 0.85
Pain treatment in arthritis-related pain: beyond NSAIDs. Open Rheumatol J (2012) 0.85
Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Obesity (Silver Spring) (2011) 0.82
Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol (2008) 0.82
Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. J Pain Res (2012) 0.82
A reverse-phase HPLC and fluorescence detection method for measurement of 5-hydroxytryptamine (serotonin) in Planaria. J Pharmacol Toxicol Methods (2004) 0.82
Cocaine and kappa-opioid withdrawal in Planaria blocked by D-, but not L-, glucose. Brain Res (2004) 0.81
Withdrawal-like behavior in planarians is dependent on drug exposure duration. Neurosci Lett (2008) 0.81
Planarians in pharmacology: parthenolide is a specific behavioral antagonist of cocaine in the planarian Girardia tigrina. Int J Dev Biol (2012) 0.80
Agmatine: identification and inhibition of methamphetamine, kappa opioid, and cannabinoid withdrawal in planarians. Synapse (2008) 0.80
Differential behavioral effect of the TRPM8/TRPA1 channel agonist icilin (AG-3-5). Eur J Pharmacol (2007) 0.80
Behavioral characterization of serotonergic activation in the flatworm Planaria. Behav Pharmacol (2008) 0.79
Opioid antagonists for pain. Expert Opin Investig Drugs (2013) 0.79
Nociceptin attenuates methamphetamine abstinence-induced withdrawal-like behavior in planarians. Neuropeptides (2008) 0.79
Extended-release formulations of tramadol in the treatment of chronic pain. Expert Opin Pharmacother (2011) 0.79
Tapentadol extended release for chronic pain patients. Adv Ther (2013) 0.79
In vivo comparison of harmine efficacy against psychostimulants: preferential inhibition of the cocaine response through a glutamatergic mechanism. Neurosci Lett (2012) 0.78
Changes in aorta alpha1-adrenoceptor number and affinity during one year of streptozotocin-induced diabetes in rats. Pharmacology (2005) 0.78
Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity. Expert Opin Drug Saf (2014) 0.78
Preliminary observations of a novel topical oil with analgesic properties for treatment of acute and chronic pain syndromes. Pain Pract (2010) 0.78
Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: III. Retinoids. J Clin Pharm Ther (2002) 0.77
Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature. J Pain Res (2012) 0.77
Looking beyond the administered drug: metabolites of opioid analgesics. J Fam Pract (2008) 0.77
Isothermal titration calorimetric study of RNase-A kinetics (cCMP --> 3'-CMP) involving end-product inhibition. Pharm Res (2004) 0.77
Glutamate carboxypeptidase II (GCPII) inhibitor displays anti-glutamate and anti-cocaine effects in an invertebrate assay. Amino Acids (2011) 0.76
Combining opioid and adrenergic mechanisms for chronic pain. Postgrad Med (2014) 0.76
Chromatography with higher pressure, smaller particles and higher temperature: a bioanalytical perspective. Bioanalysis (2010) 0.76
Pain and obesity in the older adult. Curr Pharm Des (2014) 0.76
Non-analgesic effects of opioids: factors relevant to opioid abuse and abuse- deterrent formulations. Curr Pharm Des (2012) 0.76
Acetaminophen and metabolite: lack of effect on nitric oxide synthase (constitutive or inducible). Headache (2002) 0.76
An open-label pharmacokinetic study of oxymorphone extended release in the presence of naltrexone in the older adult. J Opioid Manag (2012) 0.75
'Null method' determination of drug biophase concentration. Pharm Res (2011) 0.75
5-HT(1A)-like receptor activation inhibits abstinence-induced methamphetamine withdrawal in planarians. Neurosci Lett (2010) 0.75
Endothelin antagonists in CION injury model. Pain (2006) 0.75
In vitro tobramycin elution analysis from a novel beta-tricalcium phosphate-silicate-xerogel biodegradable drug-delivery system. J Biomed Mater Res B Appl Biomater (2004) 0.75
Evaluation of a novel topical essential oxygen oil for the treatment of pain in acute tendinopathy and sprains. Muscles Ligaments Tendons J (2011) 0.75
LiCl attenuates M(1)AChR-mediated intrathecal pilocarpine-induced reciprocal hindlimb scratching in mice. Pharmacology (2002) 0.75
The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain. Adv Ther (2015) 0.75
Cocaine synergism with α agonists in rat aorta: computational analysis reveals an action beyond reuptake inhibition. Drug Alcohol Depend (2012) 0.75
Comparison of UHPLC and HPLC methods for the assay of prostanoids: "are the methods equivalent in terms of accuracy and precision?". Bioanalysis (2011) 0.75
Is morphine medicine's biggest misnomer? Ann Pharmacother (2012) 0.75
Use of hydrophilic hydroxypropyl methacrylate/ethylene glycol methacrylate packing material in size-exclusion chromatography. J AOAC Int (2002) 0.75
Long-term efficacy, safety and tolerability of Remoxy for the management of chronic pain. Expert Rev Neurother (2015) 0.75
Intranasal ketorolac as part of a multimodal approach to postoperative pain. Pain Pract (2014) 0.75
Considerations on the use of oxymorphone in geriatric patients. Expert Opin Drug Saf (2009) 0.75
Toward the design of ribonuclease (RNase) inhibitors: ion effects on the thermodynamics of binding of 2'-CMP to RNase A. J Pharmacol Exp Ther (2002) 0.75